Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update
May 8, 2018 4:01 PM EDTTargeting DEXTENZA NDA Resubmission in the Second Quarter of 2018
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2018 and provided a business update.
We entered 2018 with an exciting set of opportunities that include a number of regulatory and clinical milestones, said Antony Mattessich, President and Chief Executive Officer. With the right strategy, objectives and leadership in... More
